Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Alzheimer's Disease
Interventions
Neramexane
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Depression, Post Traumatic Stress Disorder
Interventions
Lanicemine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Results available

Antidepressant Effects of NR2B in Major Depression

NCT00472576
Conditions
Major Depression
Interventions
MK-0657, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson's Disease
Interventions
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

NCT07593222
Conditions
Major Depression, Healthy Participants
Interventions
Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Belmont, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

NCT01585168
Conditions
Healthy
Interventions
Memantine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

GABA-glutamate Interactions and Psychosis

NCT00611572
Conditions
Cognitive Dysfunction
Interventions
iomazenil
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Tinnitus
Interventions
Ketamine Hydrochloride in saline
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D-serine, placebo, Sensory Based remediation paradigm
Drug · Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Orangeburg, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

NCT01856556
Conditions
Healthy
Interventions
NRX-1074, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pasadena, California
Conditions
Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Electrophysiological Biomarkers of AV-101

NCT03583554
Conditions
Healthy
Interventions
Placebo, AV-101 720 mg, AV-101 1440 mg
Drug
Lead sponsor
Marijn Lijffijt, PhD
Other
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Major Depressive Disorder, Depression
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Levomecor Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Dothan, Alabama • Homewood, Alabama • Anaheim, California + 32 more
Conditions
Nicotine Dependence
Interventions
GW468816, Placebo Comparator: Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Major Depressive Disorder
Interventions
NRX-1074 1 mg, Placebo, NRX-1074 5 mg, NRX-1074 10 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Oakland, California • Skokie, Illinois • Wichita, Kansas + 9 more
Conditions
Major Depression
Interventions
AV 101 (4-Chlorokynurenine), Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Opioid Use Disorder
Interventions
NYX-783, Placebo, Oxycodone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 58 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

NCT00899600
Conditions
Chronic Low Back Pain
Interventions
Ketamine, Normal saline
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
Interventions
Placebo, EG-501
Drug
Lead sponsor
Evergreen Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas